NCT05336565 PIM Incidence in Older Cardiovascular Patients During COVID-19 Pandemics
| NCT ID | NCT05336565 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| Condition | Potentially Inappropriate Medications |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-07-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to assess the incidence of potentially inappropriate medication (PIM) administration, polypharmacy, and potential drug-drug-interactions (PDDIs) in cardiovascular patients enrolled in the reimbursement program in the time of coronavirus disease (COVID-19) pandemic. Medical information system (MIS) "BARS" will be used for inclusion and retrieval of relevant data of cardiovascular patients enrolled in the reimbursement programs in the Tomsk Region. The incidence rates of PIM prescriptions will be assessed in patients aged 75 years and older. Potentially inappropriate medications will be defined according to 2015 Beers criteria. Polypharmacy will be defined as being administered five or more medications at the same time. PDDIs will be checked with Medscape Drug Interaction Checker and rated as 'Contraindicated', 'Serious', and 'Requiring Monitoring'. Combined analysis of retrospective and prospective occurrences of study parameters will be performed. PIM-BARS will evaluate the incidence rates and patterns of PIM prescriptions, polypharmacy, and PDDIs in elderly cardiovascular patients enrolled in the reimbursement program in the time of COVID-19 pandemic.
Eligibility Criteria
Inclusion Criteria: * established diagnosis of cardiovascular disease * age of 18 years and older * enrollment in the reimbursement program in Tomsk Region Exclusion Criteria: * age of 17 years and younger
Contact & Investigator
Nina D Anfinogenova, MD, PhD
PRINCIPAL INVESTIGATOR
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Frequently Asked Questions
Who can join the NCT05336565 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Potentially Inappropriate Medications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05336565 currently recruiting?
Yes, NCT05336565 is actively recruiting participants. Contact the research team at cardio.intl@gmail.com for enrollment information.
Where is the NCT05336565 trial being conducted?
This trial is being conducted at Tomsk, Russia.
Who is sponsoring the NCT05336565 clinical trial?
NCT05336565 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. The principal investigator is Nina D Anfinogenova, MD, PhD at Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences. The trial plans to enroll 1,000 participants.